NEW YORK – Exact Sciences planned acquisition of sequencing lab Ashion Analytics from the Translational Genomics Research Institute (TGen), announced this week, is part of the firm's strategy to build an end-to-end cancer testing pipeline, including diagnostics for minimal residual disease (MRD), and comes one month after the firm secured a worldwide
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.